Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Amyloidosis Channel on VJHemOnc is an independent medical education platform, supported with funding from Prothena (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EHA 2022 | Belantamab mafodotin in relapsed systemic AL amyloidosis

Jahanzaib Khwaja • 10 Jun 2022
EHA 2022
Amyloidosis Rare Diseases Antibodies Belantamab mafodotin

Jahanzaib Khwaja, MD, FRCPath, University College London Hospitals NHS Foundation Trust, London, UK, briefly discusses the results of a study investigating the efficacy of single-agent belantamab mafodotin in relapsed systemic AL amyloidosis. Overall, the study reported high overall response rates (ORR) in this patient population. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from Jahanzaib Khwaja

Daratumumab, bortezomib, thalidomide & dexamethasone in treatment-naive systemic AL amyloidosis 1:48
Daratumumab, bortezomib, thalidomide & dexamethasone in treatment-naive systemic AL amyloidosis
Jahanzaib Khwaja • 14 Jun 2025
Approaching the treatment of patients with AL amyloidosis who relapse after dara-based treatment 1:50
Approaching the treatment of patients with AL amyloidosis who relapse after dara-based treatment
Jahanzaib Khwaja • 14 Jun 2025
The impact of ethnicity on the risk stratification of systemic AL amyloidosis 1:53
The impact of ethnicity on the risk stratification of systemic AL amyloidosis
Jahanzaib Khwaja • 14 Jun 2025
Identification of an ultra-poor risk “Mayo Stage IIIC” subgroup in systemic AL amyloidosis 2:31
Identification of an ultra-poor risk “Mayo Stage IIIC” subgroup in systemic AL amyloidosis
Jahanzaib Khwaja • 14 Jun 2025

Related Videos

Results of a Phase II trial of pirtobrutinib plus venetoclax in previously treated WM 4:27
Results of a Phase II trial of pirtobrutinib plus venetoclax in previously treated WM
Jorge Castillo • 8 Dec 2025
Final report of a Phase II study of venetoclax and ibrutinib in previously untreated WM 2:54
Final report of a Phase II study of venetoclax and ibrutinib in previously untreated WM
Jorge Castillo • 8 Dec 2025
Monitoring for and managing CLS in patients with BPDCN treated with tagraxofusp-based regimens 0:47
Monitoring for and managing CLS in patients with BPDCN treated with tagraxofusp-based regimens
Andrew Lane • 6 Dec 2025
Updated results with the bispecific antibody etentamig in patients with R/R AL amyloidosis 2:17
Updated results with the bispecific antibody etentamig in patients with R/R AL amyloidosis
Vaishali Sanchorawala • 8 Dec 2025
The content of VJHemOnc is intended for healthcare professionals